Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

Administration declares monkeypox a public health emergency - Roll Call

The administration declares monkeypox a public health emergency and says it will make it easier to get vaccines to patients.

Roll Call

Monkeypox Is Giving Public Health Agencies a Chance To Prove They've Learned Nothing From COVID

Plus: Schools surveilling students online, Tim Wu leaving the White House, and more...

Reason

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The US government’s call for deep nicotine reduction in cigarettes could save millions of lives – an expert who studies tobacco addiction explains

The cigarette is the only legal consumer product that – when used as intended – causes the premature death of half of long-term users.

The Conversation

Alternate monkeypox treatment caught in regulatory delays

Axios

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.

Benzinga

5 Value Stocks to Buy Ahead of the Fall Season

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

StockNews.com

Woman shames her 'lazy dog' who would rather starve than work for his food

A woman has playfully shamed her dog who would rather skip dinner time than work for his meal - she is now giving away his dog puzzle bowl in hope 'somebody else's dog is smarter than hers'

Daily Mirror

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

Benzinga

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

The Conversation

What allegations of Alzheimer's research fraud mean for patients

Alzheimer’s disease is the most prevalent form of dementia and, with a rapidly ageing global population, it is fuelling unprecedented demand for costly patient care. There have been an estimated 400 clinical studies since the first Alzheimer’s drug trial in 1987.

The Independent UK

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Street

Can Virtual Patients Lead to Better Cell Therapies?

Biosimulation leader Certara recently inked a deal with a leading cancer research institution. Does it matter to investors?

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Monkeypox is not COVID, but need to keep a watch, says top scientist

Smallpox vaccine can protect people from getting monkeypox, says Rakesh Mishra

Benzinga

This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

The Street

Avita Medical May Be the Hidden Gem of Biotech Stocks

Avita Medical expects a big second half. Will that set the stage for a multiyear growth runway?

Investors Business Daily

FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Drops

The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.

Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1

CNBC

Benzinga

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

1 … 127 128 129 130

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.